A federal vaccine advisory committee plans to review the childhood vaccination schedule and scrutinize vaccines that have ...

Federal agencies have scheduled a series of three web-based "listening sessions" to hear from commenters about issues that might be limiting competition in the U.S. prescription drug market and ...

Generative artificial intelligence has found another home in the federal government. On Tuesday, the U.S. Food and Drug Administration announced the early launch of its very own generative AI that ...

Rescheduling marijuana to Schedule III won’t solve every problem overnight, but it is a necessary step in the right direction. This is a crucial move that will help the millions of Americans who ...

Cannabis, or marijuana, may be reclassified from a Schedule I to a Schedule III drug, loosening some federal restrictions. Here are five things to know.

Federal Drug Policy on Marijuana May See a Major ... take federal business-expense tax deductions that aren’t available to enterprises involved in “trafficking” any Schedule I or II drug.

Researching a Schedule I drug requires extensive paperwork and strict security. To obtain a Schedule I license from the DEA, researchers must submit information on how and why they plan to study ...

On May 21, the Department of Justice and Drug Enforcement Administration published a notice of proposed rulemaking to reclassify marijuana from a Schedule I drug to a Schedule III drug.

A defendant’s 'history of criminal activity' does not 'cease to exist' merely because the crime was later redefined, Justice Samuel Alito Jr. wrote for the majority.

News Supreme Court Says Later Drug Schedule Changes Don't Affect Mandatory Minimums "A defendant's 'history of criminal activity' does not 'cease to exist' merely because the crime was later ...

Schedule III drugs are still controlled substances and subject to rules and regulations, and people who traffic in them without permission could still face federal criminal prosecution.

The move started with a recommendation from the federal Health and Human Services Department, which launched a review of the drug’s status at the urging of President Biden in 2022.